right-of-way to have a single street, bike lane, brt way, boulevard for pedestrians and four lanes of traffic but a cross group thinking in integrated fashion how we are providing for the network. i will close with some of the next steps we are working on. we are coordinating the improves on franklin and golf. we are supporting other projects on the planning and design. earlier on the agenda if you can recall two hours ago you made allocations to the ongoing safety programs. these include activities such as reopening closed crosswalks. the mta is working on projects such as the lower polk bike network and advancing planning for upper polk and other projects in the design phase. finally being very supportive of two key transit spines in the neighborhood of market and van ness, which are moving

forward in the process or planning space to improve transit on the key corridors which are really the spines that the entire market and octavia neighborhood has plans around. with that it would be happy by to answer any other questions. i thank you for your attention at this late hour. >> mr. olagi. >> i just want to thank you for your presentation and look forward to the continued conversations on this issue. i worked on the market on octavia and it was pretty exciting as far as how it looked at all the different modes of, you know, transportation, walking, bicycling. we focused a lot on parking requirements at that time. at some point it might be interesting to get a sense of how that has affected or not some of the goals i think, which is to build a more sustainable neighborhood, i think. i just want to see how the

parking issue and what we did there has or has not affected the rest. you know, some analysis, i guess, would be interesting to have at this point. one of the buzz issues that i keep hearing about is the whole congestion pricing issue. i know you all have been studying it for a long time. i have gone to a couple public workshops. i don't know of any city in this country that has implemented it. i know stockholm, london has. where are we in the conversation? >> through the chair, thank you for the questions. they are timely and related. in some respects, the authority and various other agencies are advancing the pressing dialogue in a number of fashions. in 2010 the areawide cordoned pricing feasibility study was approved by the board and board directed us to seek funding to move the

analysis of congestion pricing into the phase. we have information from key stakeholders and community and other stakeholders to take a look at how does parking management get to addressing that need as well in terms of reducing that peak period congestion, making surface transit run better and providing funds to invest in mobility improvements. our present activities on pricing are along two streams. the first is we recently were awarded a grant from the federal highway administration to look at that question of how do our parking management policies sort of beyond simply managing on-street parking to an availability target, the sf park pilot, we are excited about and collect evaluation data on this fall. the next generation of parking or regulatory strategis from a demand management. this will involve a lot of data collection of private supplies of parking and the

usage of that parking, what are incentive of folks if they have that subsidized and options available to the city to use parking as a policy tool from a congestion management point of view. the second area of activity is the authority in its pending role as treasure island mobility management agency, actually have state legislation to implement congestion pricing in a very focused but important location, access to and from treasure island on the bay bridge. which is a really exciting pilot. not only from a congestion management point of view, important for performance but also from institutional and technological point of view in how we deliver and work with forecasts like caltrans who have important jurisdiction over the bridge and interests in the pricing policy and how do we deliver the project on an ongoing basis in terms of all the revenues and how

those are distributed in a set of improvements. that is very exciting. the ultimate objective of study is to say is, it is feasible and take an option as another alternative in a subsequent alternative view with congestion pricing that would be fully waived by decision makers and the public. i think this anticipates simply -- sort of lays it out to the public that we could let traffic grow as already has. it is having significant impacts on the neighborhood. we will be in trouble if we will be relying on the transit system to move people through the neighborhood and having safe n environment for bicyclists and being able to build the pedestrian environment and bicycle network we want. it is a really important dialogue. i think this helps set up that conversation, a citywide conversation about growth versus the strategies we will need from the land use side to manage that growth

effectively. >> great. we have a time frame? >> for which piece? >> the parking and the studies. >> sure. we just got our authorization from federal highway. we will be starting outside. about a year-long process. >> great. >> we will be coming back with updates and looking forward to all the commissioner's input. >> thank you. this is a great answer. >> i would say another thing to watch is san francisco transportation plan, the long-range update, which puts these issues on a countywide and even regional basis. >> i remember when i was look agent the treasure island plan, but not as it currently stands but the one that was approved about a year ago. the environmental impact report i remember having as many as over 30 significant impacts due to this whole traffic piece so it makes sense to me that this congestion pricing would be applied to this. but are we looking at

treasure island i guess preproject, right? as it is currently? as it stands currently? >> i will have him address that question. >> probably not the new project, right? interesting. >> deputy for planning. yes, we are working with tita to plan for the eventual day one of the housing perspective in 2016. currently 30 residents to eventually thousand in 2016 and 8,000 in the eventual build-out. >> if there are no comments or questions, thank you for your presentation. we can go on to public comment. seeing no one come forward we will close public comment. this is an action item so colleagues, we have a motion to move this forward to the full authority. okay. we will take that without

objection. very good. we have -- let's see. introduction of new items. >> this is an information item. >> colleagues? >> not today. >> public comment on item 11? we will close public comment. >> 12, public comment. >> again, we will -- public comment. please come forward. >> good afternoon, commissioners. jacob moody, executive director of bay view hunter's point commission for city improvement. sitting through finance and this committee i find out how complex this is dealing with all these transportation projects and how infan test millie small we are. this has quietly optered

bay view shuttle transporting hundreds to their health points in bay view, san francisco general hospital and st. lukes * allowing them to take advantage of life saving health procedures, preventive scare and lifestyle altering activities. in addition it's isn'ted toxic tours sponsored by black coalition on aids and ellis griffin to hunter's view to the housing authority mandated appointments to make sure they can remain in their housing, plus many other community activities. therefore it is disappointing our project is stuck in its process. staff around sfcta, san francisco department of public health, community health promotion and prevention and the foundation, worked on a plan proposaled to take advantage of funding for two years of operation of the health shuttle. in addition the aforementioned staff developed a plan to support

the san francisco department heal zone and fcta facility within bay view with intent of making changes in the shuttle operations agreed upon in the plan. in conversations with commissioner cohen on friday, i said that we could not operator on the budget amount or time frame offered in the proposal. perhaps question can but do so would require more negotiation with partners. it is our hope these can happen quickly and we can move forward with this project at the october commission meeting. thank you very much. >> thank you. any other members of the public who would like to comment? we will close public comment. >> 13, adjournment. >> thank you. we are adjourned.

>> it was an exciting event for those who wanted some long needed improvements. >> they saw it and they took care of it. >> the project is expected to open in spring, 2013. for more on the playground, includud

x it's my privilege to welcome and thank you, mayor lee, deputy director with the governor's office of economic office, lewis stewart, gale maderas, qb3's regkelly and esteemed colleagues of the city and dr. andres bush and the drug discovery leadership and our employees for joining us on this exciting occasion, the next step of expanding the innovation in mission bay. today is notust about the launch coelaborate , but thanks to mission bay's reputation as the hub, the area has become one of the most dynamic clusters of scientific innovation as witnessed by

pfizer and the continued expansion of nektar and growing start-up companies that number over 30 many mission bay alone complimented by ucsf and three new hospitals here in mission bay. we're thrilled as of today mission bay can add the colaborator to its growing in the area and for bayer this is another step in the company's greatest history of leadership and development and our partnering of life science firms. today we'll start the clock on what we'll hope will be a longlar of collaboration between bay area and the most innovative companies in the area. before we introduce the first companies to occupy the area

-- -- >> thank you, terry. i guess as everybody knows here, bayer has next year a history of 150 years' of successful r&d. i can assure everybody things have changed how we do r&d over the past 150 years, some things remain the same, which is you need great people talking to each other, networking and when we took a little while ago the decision to move here, it was for very simple reason. we understood that director kelly was not willing to move the whole qb3 do richmond. [ laughter ] as a consequence we wanted to have our scientists in the midst of wonderful, very inspiring campus. however, we never really gave up on the idea of getting creative young people, young start-ups to us.

and this is now happening today. establishing the collaborator will mean that we'll attract young companies working together with us on a great campus, getting inspired with great networks and helping us with the purpose of all of our doings, which is identifying breakthrough innovation for the patients which need it the most. i am extremely excited and i hope that everybody understands how important this step is for us. everybody sees that my entire management team is here, everybody understands that we have the unbelievable honor of having mayor ed lee here today, who also wants to speak to us on this event. i think we should all be proud of what we have accomplished, establishing our own group here. what we want to accomplish, establishing the collaborator. i really hope that at the end,

the big benefit will go to our patient. thank you very much. i'm very happy that mayor ed lee is here and speaks to us. thank you. >> thank you, andy. welcome everybody. you know, i still marvel, terry, and andy, at just less than ten years ago i was at dpw and we were signing off and getting rid of my mission bay driving range. signing off on getting rid of the railroads and turning this over to what was visualized by mayor brown and then gavin newsom later as the place that we're going to really create life sciences and now today, just seeing what with bay area is doing and the innovations that they have at really putting in the meat of why we all our city the innovation

capital of the world. it's not your bay area and pfizer working alone, but they are literally using their drugs and their development of drugs to really incentivize the therapeutic uses and just like with the other tech companies, this is a very successful model that is happening between big and small, established and new. the collaboration that is going to go on here, i'm excited about this. it will especially with the two companies that you are naming today and i have to admit, terry, that when i heard prolynx was here, i thought you have finally gotten a replacement for the driving range -- you have to be a golfer to understand that. [ laughter ]. and aronora, these are very important

discoveries and therapeutic uses of medin that medicine that will advance our world and 38 of them here in mission bay on a vision that i inherited, but so glad to come to fruition. these great incubators will provide information for future generations. i know. it it's right here happening in san francisco and at the same time, while we visualize the kind of push-button to some of these solutions, you have got to see how the laboratory discoveries and the very high-levels of disciplines that are happening in these laboratories. and in the constant conversation between these different disciplines that are going on. ends up to be these great

discoveries of it's exciting. it's our future. it's what we had envisioned when gavin said regenerative medicine right here in our bay, the stem-cell research going on and the association with uc san francisco that is part of your work that is happening right here. so i don't mind if i come down here every week to find out what the newest discovery is. it's amazing for the city and always places us on the map. i get to talk about this whether i'm at the u.s. conference of mayors or the democratic national convention, everybody is interested in what san francisco is doing from music to art to life sciences and clearly showing the way for our new ventures that offer even the best jobs to be created right here in san francisco. so thank you, bayer. thank you for being part of this wonderful, wonderful mix. it's my appreciate ion for you

to be here and continue to support you here and how much this has become very much a part of our city. thank you very much. [ applause ] >> mayor lee, friends and colleagues and neighbors, and partners and people who are interested in partnering with us with bayer, today is a great day. today is a day that when an idea comes relative and concrete. you can feel it and touch it and the idea goes back to terry and chris. and i'm very happy to be a part of it today. as you know, bayer is really committed to innovation and knowing the intricacies of science ever growing and becoming more complicated. it's pretty clear that we must

reach out and compliment our internal research strengths with partners, partners from academia and tech and collaborations with academia part of our research. it's not just an incubator model, but collaboration with mutual fit of interests. we help each other really for the benefit of the patients, which is really our ultimate goal to bring treatment to the impairments. the collaborator is one of the newest models that we pursue. it's an addition to our partnering models which cover actually pretty wide spans. another example i want to give you is our grants for targets initiative, where we use the internet, really to reach out into the whole crowd of scientists, worldwide, and the collaborator is our newest addition. we do have other forms of

collaboration beyond of course the collaborator and the grants for targets initiative. for example, the imi initiative in europe actually goes beyond the collaboration of individual companies forming consortia of academia and large companies where the individual partner is just too small. but focusing on this area of course, the san francisco area and mayor lee already alluded to that is a hotspot and it's extremely important. we have been here for a long time and our activities here with just four projects with ucsf last year with our partnerships are testament to that commitment to this area. and again, the collaborator is just testament to our commitment to bring treatments to the patients and we use any kind of model that fits that

purpose and makes us more productive in that endeavor. thank you. chris, please. [ applause ] >> thank you. so we have heard from my colleagues that collaboration and innovation are real priorities for bayer's research and development and using these values that are important for us. the collaborator is just an incubator, but we're trying to put a new twist on this with the landlord-tenant relationship and there really no better place to do this and to be part of the growing bioecosystem it than here in mission bay of the whole point of this is to have tenant companies, start-up companies that want to partner with bayer with proximity to our research groups in this building and in addition, can access the global

expertise of bayer scientist, as well as the infrastructure that bayer brings and dr. bush mentioned that we have had for 150 years. we are also looking to put companis in the collaborator that are not necessarily partners yet, but again, what better way to find proper probings to work on than having scientists in the same building interacting with each other? as we'll open up the space for tours the collaborator is an open-floor space that encourages interact between the start-up companies in the space. but more importantly what it brings to mission bay is the ability to interact with the 30 other start-ups here, with ucsf, and their core facilities and with incredible organizations like gladstone and qb3. really if you think about it, there probably isn't a better place in the world for a start-up company to become successful than here in mission bay. what you see here in front of me is the collaborator roster. and this will house the logos

of the start-up companies that will be the first to utilize the space. i will invite them up in a minute. aronora is developing drugs that hold the promise to prevent the growth of blood clots without some of the thrombotic side effects of bleeding. prolynx is manufacturing custom drivers - no, they are not. [ laughter ] >> exactly. statement sorry, i'm putting you in a hole now. you have to develop that as a side project. prolynx is developing technology that get as round many of the problems with conjugated drugs and develop technology for the sustained release of drugs that you can

control circulating levels and it's tuneable. so can you optimize it for each project. so with that, i would actually like to invite up aronora and prolynx. [ applause ]

>> you have heard mention from some of my colleagues -- one second -- that time is of the essence and that we are in a race to deliver the therapies to the patients and we have a clock that reminds us that we're us on the clock and time is of the essence. i would like to invite the other four speakers up to help me start the clock, that will be a reminder of what i mentioned.